[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [RiskMitigation](https://github.com/mm80843/T3.5/tree/main/docs/RiskMitigation/index.md) >> Individual ID:PBN__RiskMitigation_1186 

# __Evaluate efficacy differences based on symptoms__

## Category to which it belongs

* [Implement comprehensive, widespread testing and contact tracing programs to monitor and control the spread of the virus.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_460.md)

## Closest similar item

* [Evaluate the difference in efficacy between symptomatic and asymptomatic individuals.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2513.md)
* [Conduct clinical trials to determine the efficacy of drug therapies, develop new therapeutics](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1594.md)
* [Implement regular and widespread symptom monitoring and testing, both symptomatic and asymptomatic](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2036.md)
* [Identify missing information and develop logical relations linking drugs, coronaviruses, and conditions for drug efficacy.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1963.md)
* [Improve testing frequency and accuracy, conduct seroprevalence surveys.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2511.md)
* [Combine direct measurements with numerical simulations to inform decision-making, conduct rigorous study on intervention effectiveness](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2007.md)
* [Implementation of non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_723.md)
* [Behavior change interventions](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_869.md)
* [Non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_377.md)
* [Combining multiple screening methods, widespread testing programs.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_3046.md)

## Benefits linked to a risk

* [Tailored protection for symptomatic and asymptomatic patients](https://github.com/mm80843/T3.5/blob/main/docs/Benef/PBN__Benef_1185.md)

## Risks possibly mitigated by this Mitigation

* [Variability in disease severity in reinfected patients](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_863.md)

